ReviewMolecular bioSystems2017
Mass spectrometry for the discovery of biomarkers of sepsis.
Review in Molecular bioSystems, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 92 citations in OpenAlex.
- Metabolic footprint of sepsis and septic shock: A narrative review.World journal of critical care medicine · 2026Review
- Branched-chain amino acids and sepsis: from pathological mechanisms to clinical interventions.Nutrition & metabolism · 2025Review
- Identification of protein biomarkers to differentiate between gram-negative and gram-positive infections in adults suspected of sepsis.BMC infectious diseases · 2025Article
- Plasma proteomics in pediatric patients with sepsis- hopes and challenges.Clinical proteomics · 2025Review
- Serum metabolic profiling analysis of chronic gastritis and gastric cancer by untargeted metabolomics.Annals of medicine and surgery (2012) · 2025Article
- Investigating the efficacy of dapsone in treating sepsis induced by cecal ligation and puncture surgery in male mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Plasma Profiling of Acute Myeloid Leukemia With Fever- and Infection-Related Complications During Chemotherapy-Induced Neutropenia.Cancer reports (Hoboken, N.J.) · 2024Article
- Metabolomics Analysis and Diagnosis of Lung Cancer: Insights from Diverse Sample Types.International journal of medical sciences · 2024Review
- The State of the Art on Graphene-Based Sensors for Human Health Monitoring through Breath Biomarkers.Sensors (Basel, Switzerland) · 2023Review
- Combination of HBA1, TTR, and SERPINF2 in plasma defines phenotype correlated with severe burn outcome.iScience · 2023Article
- The Role of Coagulase-Negative Staphylococci Biofilms on Late-Onset Sepsis: Current Challenges and Emerging Diagnostics and Therapies.Antibiotics (Basel, Switzerland) · 2023Review
- The novel biomarkers for assessing clinical benefits of continuous renal replacement therapy in pediatric sepsis: a pilot study.Clinical proteomics · 2023Article
- Identifying biomarkers deciphering sepsis from trauma-induced sterile inflammation and trauma-induced sepsis.Frontiers in immunology · 2023Article
- Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques.Diagnostics (Basel, Switzerland) · 2022Review
- Peptidome profiling for the immunological stratification in sepsis: a proof of concept study.Scientific reports · 2022Article
- Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects.Rheumatology (Oxford, England) · 2022Article
- A Three-Protein Panel to Support the Diagnosis of Sepsis in Children.Journal of clinical medicine · 2022Article
- [Early predictive value of high density lipoprotein cholesterol for secondary acute kidney injury in sepsis patients].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Article
- The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review.International journal of molecular sciences · 2022Review
- Precision medicine in sepsis and septic shock: From omics to clinical tools.World journal of critical care medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Sepsis is a serious medical condition that occurs in 30% of patients in intensive care units (ICUs). Early detection of sepsis is key to prevent its progression to severe sepsis and septic shock, which can cause organ failure and death. Diagnostic criteria for sepsis are nonspecific and hinder a timely diagnosis in patients. Therefore, there is currently a large effort to detect biomarkers that can aid physicians in the diagnosis and prognosis of sepsis. Mass spectrometry is often the method of choice to detect metabolomic and proteomic changes that occur during sepsis progression. These "omics" strategies allow for untargeted profiling of thousands of metabolites and proteins from human biological samples obtained from septic patients. Differential expression of or modifications to these metabolites and proteins can provide a more reliable source of diagnostic biomarkers for sepsis. Here, we focus on the current knowledge of biomarkers of sepsis and discuss the various mass spectrometric technologies used in their detection. We consider studies of the metabolome and proteome and summarize information regarding potential biomarkers in both general and neonatal sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.